Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Blackstone Inc (BX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Blackstone Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Blackstone Inc trades at $123.33 (market cap $150.36B). The key difference: Blackstone Inc is far larger — about 3.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Blackstone Inc pays a 4.04% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BX | |
|---|---|---|
Market Cap | $39.89B | $150.36B |
Sector | Health | Financials |
52-Week High | $491.22 | $188.68 |
52-Week Low | $278.09 | $102.12 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Blackstone (BX) trades at $123.08, up 0.78% with a bullish technical signal. The stock shows strong fundamentals with revenue growth to $12.41B in 2025 and consistent earnings beats. Recent news highlights strategic moves in data centers and private equity, while analyst consensus is strongly bullish with a $147.44 price target.
Outlook remains positive driven by earnings momentum and strategic investments, though risks include market volatility and execution challenges. The current valuation at 31.56 P/E suggests premium pricing, requiring sustained growth to justify upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
